Ranitidine (Zantac) is administered intravenously at 15 mg every 80 minutes for short-term treatment of active duodenal ulcers, maintenance therapy for duodenal ulcer patients after healing of acute ulcers, treatment of gastroesophageal reflux disease, short-term treatment of active benign gastric ulcers, and treatment of pathologic GI hypersecretory conditions. It works by competitively and reversibly inhibiting histamine action at H2 receptor sites on parietal cells, thus blocking gastric acid secretion. Common side effects include headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression, hallucinations, bradycard
Ranitidine (Zantac) is administered intravenously at 15 mg every 80 minutes for short-term treatment of active duodenal ulcers, maintenance therapy for duodenal ulcer patients after healing of acute ulcers, treatment of gastroesophageal reflux disease, short-term treatment of active benign gastric ulcers, and treatment of pathologic GI hypersecretory conditions. It works by competitively and reversibly inhibiting histamine action at H2 receptor sites on parietal cells, thus blocking gastric acid secretion. Common side effects include headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression, hallucinations, bradycard
Ranitidine (Zantac) is administered intravenously at 15 mg every 80 minutes for short-term treatment of active duodenal ulcers, maintenance therapy for duodenal ulcer patients after healing of acute ulcers, treatment of gastroesophageal reflux disease, short-term treatment of active benign gastric ulcers, and treatment of pathologic GI hypersecretory conditions. It works by competitively and reversibly inhibiting histamine action at H2 receptor sites on parietal cells, thus blocking gastric acid secretion. Common side effects include headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression, hallucinations, bradycard
Name of drugs dosage and Mechanism of Indication/ response to med. responsibilities (generic and frequency of action Purpose With actual side prior to, brand name) administration effects (if any) during, and after administration Generic Name: 15 mg IVP q80 Potent anti-ulcer Short-term There are no Before: Ranitidine drug that treatment of actual side effects competitively and active duodenal reported but -Always check Brand Name: reversibly ulcer; others may the dose and Zantac inhibits histamine maintenance experience the expiry action at H2- therapy for following adverse date before Drug receptor sites on duodenal ulcer reaction: giving to patient Classification: parietal cells, patient after Gastrointestinal thus blocking healing of CNS:Headache, -Check Patient’s agent; gastric acid acute ulcer; malaise, medical Record antisecretory secretion. treatment of dizziness, if the patient is (h2-receptor Indirectly reduces gastroesophage somnolence, contraindicated antagonist) pepsin secretion al reflux insomnia, to the but appears to disease; short- vertigo, mental medication have minimal term treatment confusion, effect on fasting of active, agitation, -Observe the 12 and postprandial benign gastric depression, rights of drug serum gastrin ulcer; treatment hallucinations in administration concentrations or of pathologic older adults. secretion of GI -Inform the gastric intrinsic hypersecretory CV:Bradycardia patient and factor or mucus. conditions (with rapid IV the guardian (e.g., Zollinger- push). that the THERAPUETIC Ellison medication effects: syndrome, GI:Constipation, may cause systemic nausea, drowsiness, Blocks daytime mastocytosis, abdominal pain, dizziness, or and nocturnal and diarrhea. fatigue basal gastric acid postoperative secretion hypersecretion) Skin:Rash. During: stimulated by ; heartburn. histamine and -Administer Hematologic:Re reduces gastric the medicine versible decrease acid release in slowly in WBC count, response to food, thrombocytopeni pentagastrin, and After: a. insulin. Shown to inhibit 50% of -Monitor for the stimulated adverse gastric acid reactions. secretion.